Relapse After Venetoclax-Based Therapy: Early vs Late Management

Video content above is prompted by the following:

• Briefly review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy. (ESMO CLL Guideline Update 2024)
• Briefly comment on the underlying rationale and supporting data (high level) for continuous BTKi therapy in this setting.
  • ALPINE – Brown, et al. ASH 2023. Abstract 202
  • ELEVATE-RR– Seymour, et al. Blood. 2023
  • How do you incorporate these data and recommendations into your treatment approach?

Late Relapse After 1L Venetoclax

• Briefly review recent ESMO guideline updates for managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy.
  • How do you define early versus late relapse, and how does your treatment approach differ for each following venetoclax-based time-limited therapy?
  • At what point do you consider retreatment with venetoclax?